Author/Authors :
Shirvani, M Infectious Diseases Research Center - Kermanshah University of Medical Sciences - Kermanshah, Iran , Sayad, B Infectious Diseases Research Center - Kermanshah University of Medical Sciences - Kermanshah, Iran , Shojaei, L Department of Clinical Pharmacy - Faculty of Pharmacy - Kermanshah University of Medical Sciences - Kermanshah, Iran , Amini, A Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center - Faculty of Pharmacy - Tehran University of Medical Sciences - Tehran, Iran , Shahbazi, F Department of Clinical Pharmacy - Faculty of Pharmacy - Kermanshah University of Medical Sciences - Kermanshah, Iran
Abstract :
Recently, remdesivir was approved by the United States Food and Drug Administration for patients with Coronavirus disease
2019 (COVID-19). We herein describe 3 patients with COVID-19 who showed significant bradycardia and QTc prolongation
after remdesivir administration. Bradycardia did not respond to atropine treatment in 2 of the patients, one of whom received
theophylline and the other required a temporary pacemaker. Fortunately, the patients’ heart rate and rhythm returned to
normal after the discontinuation of remdesivir, albeit it lengthened their hospital stays. Careful monitoring during remdesivir
infusion may decrease the risk of adverse cardiovascular side effects.
Keywords :
Remdesivir , COVID-19 , Bradycardia , cardiac , Arrhythmias
